CANDEL THERAPEUTICS, INC.
Last · NASDAQ$9.07-0.20 (-2.16%)close · yahoo · 15h ago
Market cap$694.02M76.5M sh
P/E · TTM-6.2fwd -14.5 · eps -1.46 · loss
Beta-0.31vs S&P 500
Div yield0.00%annual · TTM
52w range
$4.35$14.00
Volume988.8Ksession
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-12
- Operating Cf Burn
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Accumulated Deficit High — Accumulated deficit / equity 444%
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.31
Est. revenue
0
Press & signals
- GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
- GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans